{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T18:37:52Z","timestamp":1776623872075,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,19]]},"DOI":"10.7759\/cureus.107352","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:42:31Z","timestamp":1776620551000},"source":"Crossref","is-referenced-by-count":0,"title":["Tumor Regression Following Neoadjuvant Therapy as a Determinant of Surgical Resectability in Stage IIIA Non-small Cell Lung Cancer: A Comparative Clinical Study"],"prefix":"10.7759","author":[{"given":"Safet","family":"Musanovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilijaz","family":"Pilav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alen","family":"Pilav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Custovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatan","family":"Zvizdic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer","volume":"11","author":"Goldstraw P","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al.. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016, 11:39-51. 10.1016\/j.jtho.2015.09.009","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Riely GJ","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, et al.. Non-small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024, 22:249-74. 10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Canc Netw"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00249","article-title":"Surgical management of stage IIIA non-small-cell lung cancer","volume":"7","author":"Van Schil PE","year":"2017","unstructured":"Van Schil PE, Berzenji L, Yogeswaran SK, Hendriks JM, Lauwers P. Surgical management of stage IIIA non-small-cell lung cancer. Front Oncol. 2017, 7:249. 10.3389\/fonc.2017.00249","journal-title":"Front Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO consensus conference in lung cancer: locally advanced stage III-non-small-cell lung cancer","volume":"26","author":"Eberhardt WE","year":"2015","unstructured":"Eberhardt WE, De Ruysscher D, Weder W, et al.. 2nd ESMO consensus conference in lung cancer: locally advanced stage III-non-small-cell lung cancer. Ann Oncol. 2015, 26:1573-88. 10.1093\/annonc\/mdv187","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60737-6","article-title":"Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial","volume":"374","author":"Albain KS","year":"2009","unstructured":"Albain KS, Swann RS, Rusch VW, et al.. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009, 374:379-86. 10.1016\/S0140-6736(09)60737-6","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70156-6","article-title":"Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer","volume":"9","author":"Thomas M","year":"2008","unstructured":"Thomas M, R\u00fcbe C, Hoffknecht P, et al.. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol.. 2008, 9:636-48. 10.1016\/S1470-2045(08)70156-6","journal-title":"Lancet Oncol."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70172-X","article-title":"Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial","volume":"10","author":"Stupp R","year":"2009","unstructured":"Stupp R, Mayer M, Kann R, et al.. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009, 10:785-93. 10.1016\/S1470-2045(09)70172-X","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann MD","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN Jr, et al.. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014, 15:e42-50. 10.1016\/S1470-2045(13)70334-6","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318247504a","article-title":"Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy","volume":"7","author":"Pataer A","year":"2012","unstructured":"Pataer A, Kalhor N, Correa AM, et al.. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012, 7:825-32. 10.1097\/JTO.0b013e318247504a","journal-title":"J Thorac Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezx122","article-title":"Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma","volume":"52","author":"Casiraghi M","year":"2017","unstructured":"Casiraghi M, Maisonneuve P, Brambilla D, et al.. Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2017, 52:975-81. 10.1093\/ejcts\/ezx122","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2009.04.102","article-title":"Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does \"side\" really matter?","volume":"88","author":"Kim AW","year":"2009","unstructured":"Kim AW, Faber LP, Warren WH, et al.. Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does \"side\" really matter?. Ann Thorac Surg. 2009, 88:937-43; discussion 944. 10.1016\/j.athoracsur.2009.04.102","journal-title":"Ann Thorac Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.09.063","article-title":"Pneumonectomy for lung cancer: contemporary national early morbidity and mortality outcomes","volume":"149","author":"Thomas PA","year":"2015","unstructured":"Thomas PA, Berbis J, Baste JM, et al.. Pneumonectomy for lung cancer: contemporary national early morbidity and mortality outcomes. J Thorac Cardiovasc Surg. 2015, 149:73-82. 10.1016\/j.jtcvs.2014.09.063","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.05.68","article-title":"Pathologic complete response after induction therapy-the role of surgery in stage IIIA\/B locally advanced non-small cell lung cancer","volume":"10","author":"Schreiner W","year":"2018","unstructured":"Schreiner W, Gavrychenkova S, Dudek W, Rieker RJ, Lettmaier S, Fietkau R, Sirbu H. Pathologic complete response after induction therapy-the role of surgery in stage IIIA\/B locally advanced non-small cell lung cancer. J Thorac Dis. 2018, 10:2795-803. 10.21037\/jtd.2018.05.68","journal-title":"J Thorac Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.040","article-title":"Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial","volume":"21","author":"Betticher DC","year":"2003","unstructured":"Betticher DC, Hsu Schmitz SF, T\u00f6tsch M, et al.. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003, 21:1752-9. 10.1200\/JCO.2003.11.040","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.09.003","article-title":"Clinical significance of downstaging in patients with limited-disease small-cell lung cancer","volume":"15","author":"Go SI","year":"2014","unstructured":"Go SI, Keam B, Kim TM, et al.. Clinical significance of downstaging in patients with limited-disease small-cell lung cancer. Clin Lung Cancer. 2014, 15:e1-6. 10.1016\/j.cllc.2013.09.003","journal-title":"Clin Lung Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2010.07.092","article-title":"Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors","volume":"141","author":"Paul S","year":"2011","unstructured":"Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, Altorki NK. Survival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011, 141:48-58. 10.1016\/j.jtcvs.2010.07.092","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1880","article-title":"Concurrent cisplatin\/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805","volume":"13","author":"Albain KS","year":"1995","unstructured":"Albain KS, Rusch VW, Crowley JJ, et al.. Concurrent cisplatin\/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995, 13:1880-92. 10.1200\/JCO.1995.13.8.1880","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.02.002","article-title":"The role of surgery in stage IIIA non-small cell lung cancer","volume":"19","author":"Eberhardt WE","year":"2005","unstructured":"Eberhardt WE, Hepp R, Stamatis G. The role of surgery in stage IIIA non-small cell lung cancer. Hematol Oncol Clin North Am. 2005, 19:303-19, vi-vii. 10.1016\/j.hoc.2005.02.002","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/BF01192200","article-title":"Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment","volume":"123","author":"Junker K","year":"1997","unstructured":"Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, M\u00fcller KM. Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol. 1997, 123:469-77. 10.1007\/BF01192200","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Mariano Provencio","year":"2020","unstructured":"Mariano Provencio, Ernest Nadal, Amelia Insa, et al.. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020, 21:1413-22. 10.1016\/S1470-2045(20)30453-8","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis WD","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al.. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015, 10:1243-60. 10.1097\/JTO.0000000000000630","journal-title":"J Thorac Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-770","article-title":"A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient","volume":"9","author":"Gao P","year":"2020","unstructured":"Gao P, Chen H, Zeng T, et al.. A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient. Transl Lung Cancer Res. 2020, 9:2157-60. 10.21037\/tlcr-20-770","journal-title":"Transl Lung Cancer Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S195010","article-title":"Risk factors of postoperative pulmonary complications after minimally invasive anatomic resection for lung cancer","volume":"15","author":"Yang R","year":"2019","unstructured":"Yang R, Wu Y, Yao L, Xu J, Zhang S, Du C, Chen F. Risk factors of postoperative pulmonary complications after minimally invasive anatomic resection for lung cancer. Ther Clin Risk Manag. 2019, 15:223-31. 10.2147\/TCRM.S195010","journal-title":"Ther Clin Risk Manag"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000096041.13859.AB","article-title":"Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy","volume":"16","author":"Liu-Jarin X","year":"2003","unstructured":"Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol. 2003, 16:1102-8. 10.1097\/01.MP.0000096041.13859.AB","journal-title":"Mod Pathol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2005.06.066","article-title":"Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial","volume":"81","author":"Allen MS","year":"2006","unstructured":"Allen MS, Darling GE, Pechet TT, et al.. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006, 81:1013-20. 10.1016\/j.athoracsur.2005.06.066","journal-title":"Ann Thorac Surg"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli A","year":"2009","unstructured":"Brunelli A, Charloux A, Bolliger CT, et al.. ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009, 34:17-41. 10.1183\/09031936.00184308","journal-title":"Eur Respir J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446690-tumor-regression-following-neoadjuvant-therapy-as-a-determinant-of-surgical-resectability-in-stage-iiia-non-small-cell-lung-cancer-a-comparative-clinical-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T17:42:32Z","timestamp":1776620552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446690-tumor-regression-following-neoadjuvant-therapy-as-a-determinant-of-surgical-resectability-in-stage-iiia-non-small-cell-lung-cancer-a-comparative-clinical-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.107352","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}